Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)

Date: 30 September 2019

According to a research report published by Azoth Analytics in September 2019, Prader-Willi Syndrome therapeutics market was valued at USD 2.2 billion in year 2018. Global Prader-Willi Syndrome market is expected to grow rapidly on the back of the increasing number of patients.
The global market of PWS Therapeutics market is likely to grow in the forecast period with the expected launch of DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) and Lariglutide (Novo Nordisk). The launch of these drugs is anticipated to provide higher momentum to the market growth. 

Prader-Willi Syndrome (PWS) is a rare genetic disorder affecting approximately 1 in 15,000 births, as per the International Prader-Willi Syndrome Organization. Currently pharmacological management of Prader-Willi Syndrome focuses largely on the use of human growth hormone to improve growth and body composition. Somatropin based hGH is currently available therapy in the market, which was first launched by Pfizer in the United States and now have many biosimilars in the global market. 

Currently high adoption rate of hGH Somatropin to increase height, muscle mass, stamina, bone density of PWS patients has been primarily driving the market growth.
Expected launch of therapies, such as DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) and Lariglutide (Novo Nordisk) have the potential to create a positive shift in the PWS market size. Moreover, factors such increasing patient pool, growing therapy coverage rate, increasing government involvement, and growing availability of hGH at lower or subsidized price is anticipated to provide higher momentum to the market growth in the forecast period.

Rising awareness and presence of well-developed medical facilities is expected to give rise to the number of diagnosed patients in the United States, which will further increase the demand for the treatment options in the country. 

...